High Touch vs Usual Care: Number of Staff Who Received SARS-CoV-2 Vaccine
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.542 | 0.531 | 0.554 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.533 | 0.522 | 0.543 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00972 | -0.00564 | 0.0251 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.99 | 1.05 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.978 | 1.11 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on High Touch than on Usual Care | 103 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | High Touch | Facilities in the 'high touch' arm will receive the same electronic messaging and educational material as in the 'usual care' arm but will receive an additional high touch multi-pronged behavioral intervention.~High touch multi-pronged behavioral intervention: In this intervention, facilities will work with our research team to accomplish the following:~1. Identify and engage a Facility Opinion Leader.~2. Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~3. Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~4. Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~5. Acquire additional COVID-19 testing kits using funds provided by our research team. | 4,098 | 7,555 | OG001 | ClinicalTrials.gov |
| Group 2 | Usual Care | Facilities in the 'usual care' arm will be offered electronic messaging and education regarding the COVID-19 vaccine. This material stems from the Centers for Disease Control and Prevention (CDC) and AMDA - The Society for Post-Acute and Long-Term Care Medicine (AMDA) resources and represents a suggested approach to reduce vaccine hesitancy in staff and residents/proxies (e.g., legally authorized representatives, powers of attorney). This electronic quality improvement (QI) material will be developed as part of a QI initiative and disseminated by the American Health Care Association (AHCA) to the SNF chains and using social media. | 4,643 | 8,716 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Staff Who Received SARS-CoV-2 Vaccine | ClinicalTrials.gov |
| Description | A binary measure (Yes or No) indicating whether a staff member received any dose of a SARS-CoV-2 vaccine, identified by the facility log within the study period. | ClinicalTrials.gov |
| Time frame | 15 weeks | ClinicalTrials.gov |
| Population | Number of staff was estimated using the total number of unique staff identified in these facilities with PBJ (payroll based journal) data averaged over the last two quarters of 2020. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Improving COVID-19 Vaccine Uptake in Nursing Homes | ClinicalTrials.gov |
| NCT number | NCT04732819 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | COVID-19 Vaccines | ClinicalTrials.gov |
| Interventions | High touch multi-pronged behavioral intervention | ClinicalTrials.gov |
| Lead sponsor | Brown University | ClinicalTrials.gov |
| Results first posted | 2021-09-05 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04732819?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.